Published on: July 10, 2026
Dehradun, 10 July 2026: Reinforcing its commitment to advancing ethical, innovative, and patient-centred clinical research, the Department of Clinical Research, Himalayan Institute of Medical Sciences (HIMS), Swami Rama Himalayan University (SRHU) successfully organized a one-day national symposium titled “Clinical Research Catalyst: Accelerating Science from Proposal to Patient.” The symposium was sponsored by the Department of Health Research (DHR), Ministry of Health & Family Welfare, Government of India, 103 participants from diffent colleges participated in this vent.The symposium was graced by Dr. Seema Pai, Senior Director Clinical Site Operations (India/ SEA), Pfizer, Mumbai, as the Chief Guest, while the Hon’ble Vice Chancellor, Prof. (Dr.) Rajendra Dobhal, presided over the inaugural session. The event brought together eminent clinicians, researchers, academicians, pharmaceutical industry leaders, regulatory experts, healthcare professionals, and students on a common platform to deliberate on emerging trends, innovations, regulatory advancements, funding opportunities, and patient-centred approaches in clinical research. The symposium featured distinguished speakers from leading government organizations, industry, and innovation sectors, including Dr. Gunjan Kumar, Scientist-D, Indian Council of Medical Research (ICMR); Dr. Sneha Gupta, Director, IQVIA; Dr. Gajendrasinh Chanchu, Chief Operating Officer, HomeNurse4U; and Dr. Amjad Hussain, Chief Executive Officer, ACIC–SIIC (Atal Community Innovation Centre – SRHU Innovation & Incubation Centre). The programme commenced with a welcome address by Dr. Ahmadulla Shariff, who warmly welcomed the distinguished guests, speakers, faculty members, industry experts, and participants. In his address, he emphasized the importance of conducting clinical research with the highest standards of ethics, scientific integrity, and regulatory compliance. He highlighted the evolving landscape of clinical trials and encouraged researchers to embrace innovation while ensuring participant safety and adherence to Good Clinical Practice (GCP).
Delivering the inaugural address, Prof. (Dr.) Rajendra Dobhal, Hon’ble Vice Chancellor, SRHU, underscored the pivotal role of scientific research and innovation in transforming healthcare. Referring to the Charaka Samhita, he highlighted India’s rich scientific heritage and emphasized the need to translate traditional knowledge into evidence-based medical research. Reflecting on the present pharmaceutical landscape, he observed that while remarkable progress has been achieved, there remains a significant need for breakthrough innovations in drug discovery and development. He encouraged researchers to move beyond incremental advances and pursue original scientific discoveries that address unmet clinical needs. He also highlighted the transformative role of Artificial Intelligence (AI) in accelerating drug development, optimizing clinical trial processes, enabling precision medicine, and improving patient outcomes.
Addressing the gathering as the Dr. Seema Pai, , emphasized the rapidly evolving landscape of oncology clinical research and the transformative impact of precision medicine on cancer care. She highlighted recent advances in antibody-drug conjugates, bispecific antibodies, cell and gene therapies, radiopharmaceuticals, and AI-enabled clinical trial methodologies. Stressing the importance of patient-centred drug development and innovative clinical trial designs, she encouraged young researchers to embrace scientific excellence, interdisciplinary collaboration, and ethical research practices to advance healthcare innovation.
The scientific programme featured a series of expert lectures delivered by distinguished speakers from academia and the pharmaceutical industry. Dr. Monika Bahl delivered an insightful session on ethical excellence in clinical research, emphasizing participant rights, informed consent, confidentiality, risk-benefit assessment, and compliance with ICH-GCPand ICMR National Ethical Guidelines. She reiterated that participant welfare and safety must always remain the highest priority throughout the clinical research lifecycle.
Delivering an inspiring lecture on innovation beyond conventional boundaries, Dr. Amjad Hussain showcased pioneering developments in CAR-T cell therapy, precision oncology, CRISPR-based genome editing, patient-derived organoid models, and AI-enabled immunotherapy research. He highlighted how cutting-edge technologies are revolutionizing personalized cancer treatment and shared his internationally recognized research contributions in next-generation immunotherapy.
Highlighting the importance of patient-centred research, Mr. Gajendrasinh Chanchu emphasized transforming patients from passive trial participants into active research partners. He discussed decentralized clinical trials, telemedicine, home healthcare support, mobile nursing, and personalized patient services that improve trial accessibility, participant engagement, retention, and overall research quality.
The symposium also focused on strengthening research funding and collaborative innovation. Dr. Gunjan Kumar provided an overview of funding opportunities available through agencies such as ICMR, DBT/BIRAC, DST-SERB, CSIR, ANRF, NIH, and the Wellcome Trust, highlighting the importance of translational research, entrepreneurship, and academia-industry collaboration. Complementing this perspective, Dr. Sneha Gupta discussed India’s evolving regulatory framework, digital transformation in clinical research, Quality by Design (QbD), electronic trial management systems, and collaborative strategies required to position India as a globally competitive destination for high-quality clinical research.
A major highlight of the symposium was the high-level panel discussion titled “Transforming Cancer Care Through Cell Therapy: Navigating Innovation, Investment and Clinical Trials.” The panel brought together leading experts from academia and industry to deliberate on scientific innovations, commercialization challenges, regulatory pathways, investment opportunities, and the future of cell and gene therapies in India. The discussion emphasized the importance of multidisciplinary collaboration in translating advanced scientific discoveries into accessible and effective patient care.
The symposium witnessed enthusiastic participation from faculty members, clinicians, researchers, postgraduate students, healthcare professionals, and representatives from academia and the pharmaceutical industry. The scientific deliberations reinforced the importance of ethical research practices, interdisciplinary collaboration, technological innovation, sustainable funding mechanisms, and patient-centred approaches in strengthening India’s clinical research ecosystem.
The symposium concluded with closing remarks by Dr. Nikku Yadav, Principal Investigator of the Department of Health Research (DHR)-sponsored project, Dr. Yadav emphasized that meaningful collaboration among academia, industry, clinicians, researchers, funding agencies, and regulatory authorities is essential for accelerating the translation of scientific discoveries into patient-centred healthcare solutions. He reiterated that innovation, ethical clinical research, capacity building, strategic partnerships, and sustained investment in research are fundamental to strengthening India’s clinical research ecosystem. Dr. Yadav expressed his sincere gratitude to the Department of Health Research, Ministry of Health & Family Welfare, Government of India, for sponsoring the symposium and acknowledged the invaluable contributions of the Chief Guest, distinguished speakers, panellists, delegates, participants, organizing committee members, and volunteers for making the event a grand success. The following members were present: Dr. Shriff, Dr. Bindu Dey, Dr. Ruchi Juyal, Dr. Monika Bahl, Dr. Amjad Hussain, Dr. Gunjan Kumar, Dr. Sneha Gupta, Dr. Saurabh Kohli, Dr. D. C. Dhasmana, Dr Nikku Yadav, Dr. Manisha Sharma, and Ms. Charu Paliwal.